RecallRadar

FDA Drug recall D-0250-2021

Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc

On 2021-02-17 the FDA classified a Class III recall of Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc by Accord Healthcare, citing labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0250-2021
ClassificationClass III
Statusterminated
Initiated2021-01-28
Published2021-02-17
Last updated2026-09-13 11:52 UTC
CompanyAccord Healthcare
DistributionUS

Product

Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA. Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)

Reason

Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials

Identifiers

ndc16729-471-08
ndc16729-472-08
ndc16729-473-03
ndc16729-474-03
ndc16729-474-05
ndc16729-472-30
code_infoLot: M2013645 Exp. Aug. 2022

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0250-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.